Inhibrx Biosciences Reports Q2 2026 Financial Results

What Happened
Inhibrx Biosciences, Inc. (INBX) filed a Form 8-K on August 13, 2026 under Item 2.02 to announce its results of operations and financial condition for the three and six months ended June 30, 2026. The company furnished a press release reporting those results as Exhibit 99.1 to the filing; the cover page Inline XBRL file is provided as Exhibit 104. The report is signed by Chief Financial Officer Kelly Deck.

Key Details

• Filing date: August 13, 2026 (Form 8-K).
• Period covered: three and six months ended June 30, 2026 (Q2 2026 and year-to-date).
• Press release containing the financial results furnished as Exhibit 99.1.
• Report signed by CFO Kelly Deck; Inline XBRL cover page included as Exhibit 104.

Why It Matters
This 8-K signals that Inhibrx has publicly released its quarterly and half-year financial results; those results (revenue, net income/loss, cash position, and any operational updates) are contained in the furnished press release. Retail investors should review Exhibit 99.1 or the company’s investor relations materials to see the specific financial figures and any management commentary or guidance that could affect valuation and near-term stock movement.